MiNA Therapeutics

MiNA Therapeutics is a clinical-stage biotechnology company pioneering small activating RNA medicines, a class of oligonucleotide therapeutics that restore or boost expression of underactive genes by activating transcription rather than silencing it.

The approach targets diseases driven by loss of normal gene function, including sickle cell disease, hepatocellular carcinoma, and hereditary angioedema.

MiNA advances its clinical pipeline while licensing its RNA activation platform to pharmaceutical partners including Boehringer Ingelheim, Eli Lilly, BioMarin and Nippon Shinyaku.